Fabhalta (iptacopan) — NDA/BLA submission
2026
Full data will be presented at future medical meetings and included in regulatory submissions in 2026.Source filing
NVS biotech catalysts & pipeline
NOVARTIS AG · Data as of 2026-09-08
Upcoming catalysts
Rhapsido (remibrutinib) — Topline data
2026
Full study readout and submission for the remaining two subtypes of CINDU expected in 2026.Source filing
del-desiran — Topline data
H2 2026
Del-desiran is currently being evaluated in the Phase III HARBOR study in DM1, with readout anticipated in H2 2026.Source filing
ianalumab — NDA/BLA submission
2027
Data presented at ASH, simultaneously published in NEJM, and will be included in regulatory submissions in 2027.Source filing
Zigakibart — Topline data
H1 2027
Zigakibart is currently being evaluated in the Phase III BEYOND study in adults with IgAN, with readout anticipated in H1 2027.Source filing
Rhapsido (remibrutinib) — Conference presentation
Oct 21–Oct 23
Novartis will present the REMODEL-1 and REMODEL-2 data as a late-breaker at MSToronto2026 and intends to host an investor call following the congress presentation.Source filing